TSE:TRIL Trillium Therapeutics - TRIL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day RangeC$23.33▼C$23.3352-Week Range N/AVolume60,423 shsAverage Volume166,586 shsMarket CapitalizationC$2.45 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions ChainSocial Media About Trillium Therapeutics (TSE:TRIL) StockTrillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.Read More Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRIL Stock News HeadlinesMarch 13, 2023 | finance.yahoo.comRatio Therapeutics Appoints Dr. Noel Monks as Head of BiologyMarch 13, 2023 | reuters.comFactbox: Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spreeMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. February 24, 2023 | benzinga.comAllogene Therapeutics Stock (NASDAQ:ALLO), Quotes and News SummaryFebruary 23, 2023 | finance.yahoo.comTvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast CancerFebruary 6, 2023 | markets.businessinsider.comViridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan ViolinOctober 26, 2022 | finance.yahoo.comAlex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxietyAugust 5, 2022 | finance.yahoo.comPfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. July 29, 2022 | ca.finance.yahoo.comLeukemia Therapeutics Global Market Report 2022July 18, 2022 | thestreet.comTrillium Therapeutics Inc. NewsJune 10, 2022 | finance.yahoo.comRatio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of CancersMay 10, 2022 | finanznachrichten.deBloom Burton & Co. Inc.: Three Finalists Announced for the 2022 Bloom Burton AwardJanuary 26, 2022 | finance.yahoo.comGenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation BioDecember 16, 2021 | au.finance.yahoo.comCD47 Targeting Global Therapeutics Market 2021-2035, by Target Disease Indication, Type of Molecule Key Players and Key Geographical RegionsOctober 28, 2021 | finance.yahoo.comTrillium Therapeutics Receives Final Court Order Approving ArrangementOctober 26, 2021 | theglobeandmail.comShareholders of cancer-drug developer Trillium Therapeutics approve takeover by Pfizer Inc.October 26, 2021 | finance.yahoo.comTrillium Securityholders Approve Acquisition by PfizerOctober 5, 2021 | finance.yahoo.comIs Trillium Therapeutics Inc. (TSE:TRIL) Popular Amongst Institutions?September 14, 2021 | markets.businessinsider.comHere's the Biotech Pfizer Should Consider Acquiring NextAugust 26, 2021 | finance.yahoo.comINVESTIGATION: Halper Sadeh LLP Investigates LMRK, HFC, NLOK, TRIL, LDL; Shareholders are Encouraged to Contact the FirmAugust 24, 2021 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Trillium Therapeutics Inc. (Nasdaq – TRIL)August 23, 2021 | businesswire.comTRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium ...August 23, 2021 | thestreet.comTop 5 Stock Gainers for Monday: Pfizer, Trillium, NextGen, VivosAugust 23, 2021 | markets.businessinsider.comMid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Trillium TherapeuticsAugust 23, 2021 | finance.yahoo.comPfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See HighlightsAugust 23, 2021 | finance.yahoo.comWhy Trillium Therapeutics Stock Is Skyrocketing TodaySee More Headlines Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:TRIL Previous SymbolTSE:SSS CUSIPN/A CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.27 Current Ratio12.04 Quick Ratio11.54 Sales & Book Value Annual SalesC$43,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.77 Book ValueC$2.17 per share Price / BookN/AMiscellaneous Outstanding Shares104,995,000Free FloatN/AMarket CapC$2.45 billion OptionableOptionable BetaN/A Key ExecutivesDr. Jan Skvarka (Age 54)Pres, CEO & Director Comp: $812.5kMr. James T. Parsons C.A. (Age 56)C.P.A., MAcc, CPA-CA, Chief Financial Officer Comp: $543.38kDr. Robert Uger (Age 50)Chief Scientific Officer Comp: $595.73kDr. Penka Petrova (Age 53)Chief Devel. Officer Comp: $553.53kDr. Ingmar Bruns M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $230kBenjamin LookerGen. CounselDr. Rosemary Harrison (Age 38)Sr. VP of Corp. Devel. & Strategy Dr. Michael G. HillHead of Calgary SiteMs. Kathleen Large (Age 61)Sr. VP - Clinical Operations More ExecutivesKey CompetitorsBELLUS HealthTSE:BLUConcordia InternationalTSE:CXRCronos GroupTSE:CRONdentalcorpTSE:DNTLCanopy GrowthTSE:WEEDView All Competitors TRIL Stock - Frequently Asked Questions What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ). What is Trillium Therapeutics' stock symbol? Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL." How do I buy shares of Trillium Therapeutics? Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. How much money does Trillium Therapeutics make? Trillium Therapeutics (TSE:TRIL) has a market capitalization of C$0.00 and generates C$43,000.00 in revenue each year. How can I contact Trillium Therapeutics? Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The official website for the company is www.trilliumtherapeutics.com. The company can be reached via phone at +1-416-5950627. This page (TSE:TRIL) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.